| Name | atracurium besylate |
|---|---|
| Synonyms |
2,2'-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-Isoquinolinium, benzenesulfonate (1:2)
(1R,2R)-1-[(3,4-diMethoxyphenyl)Methyl]-2-(3-{[5-({3-[(1R,2R)-1-[(3,4-diMethoxyphenyl)Methyl]-6,7-diMethoxy-2-Methyl-1,2,3,4-tetrahydroisoquinolin-2-iuM-2-yl]propanoyl}oxy)pentyl]oxy}-3-oxopropyl)-6,7-diMethoxy-2-Methyl-1,2,3,4-tetrahydroisoquinolin-2-iuM Atracurium for impurity F identification CRS NIMBEX AtracuriumBesylate(DMF) Atracurium besylate, a neuromusculblocking agent AtracuriuM besylate (TracriuM) Pentamethylen bis(3-(1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4-dimethoxybenzyl)-2-methyl-2-isochinolyl)propionat)bis(benzolsulfonat) 2,2'-((Pentane-1,5-diylbis(oxy))bis(3-oxopropane-3,1-diyl))bis(1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium) benzenesulfonate EINECS 264-743-4 AttracuriumBesylate 2,2'-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)meth 51W-89:Nimbex Atracurim besylate ATRACURIUMBESYLATE BW-33A Tracur CIS-ATRACURIUM BESYLETE atracurium besilate [INN_en] Wellcome 33A74 2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-{[3,4-bis(methyloxy)phenyl]methyl}-2-methyl-6,7-bis(methyloxy)-1,2,3,4-tetrahydroisoquinolinium] bisbenzenesulfonate 2,2’-[1,5-Pentanediylbis[oxy(3-oxcr3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinolinium]dibenzenesulfonate 2,2'-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-isoquinolinium dibenzenesulfonate CisatracuriumBesilete Atracurium Dibesylate ATRACURIUM BESYLATE /BP 2,2'-[1,5-Pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-isoquinolinium Benzenesulfonate Atracurim besylate Bp 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoic acid 5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydr 2,2'-{Pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium] bisbenzenesulfonate ATRACURIUM BESYLAT tracurium Besylate Atracurium besilate CRS Atracuricum Besilate Bensulfuramtorisone ATRACURIUM BESILATE INJECTION Atracurium besilate API BW-33A, Tracrium, 2,2μ-[1,5-Pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinolinium]dibenzenesulfonate Atracurium besylate a neuromusculblocking agent ATRICURIUM BESYLATE TRACRIUM Atraeurium Besylate Atracurium Besylate (BW-33A) Atracurium besylate,2,2′-[1,5-Pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinolinium]dibenzenesulfonate, BW-33A, Tracrium Atracurium besylate, >= Atracurium Besylate Cisatracurium Atracurium besilate (Y0000424) ATRACURIUM BESILATE Atracurium Besylate MFCD00797403 inflammatory,anticancer,Inhibitor,Atracurium besylate,neuromusculblockade,inhibit,nAChR,GSC cells,Nicotinic acetylcholine rectors,bronchoconstriction 2,2'-{Pentan-1,5-diylbis[oxy(3-oxopropan-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisochinolinium]bisbenzolsulfonat Atracurium benzenesulfonate Isoquinolinium, 2,2'-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl- benzenesulfonate (1:2) 2,2'-[1,5-PENTANEDIYLBIS[OXY(3-OXO-3,1-PROPANEDIYL)]]BIS[1-[3,4-DIMETHOXYPHENYL)METHYL]-1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-2-METHYLISOQUINOLINIUM]DIBENZENESULFONATE Atraculum besylate Isoquinolinium, 2,2'-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, dibenzenesulfonate bisbenzènesulfonate de 2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-diméthoxybenzyl)-6,7-diméthoxy-2-méthyl-1,2,3,4-tétrahydroisoquinoléinium] 2,2'-{1,5-Pentanediylbis[oxy(3-oxo-3,1-propanediyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium] bisbenzenesulfonate Atracurium Besylate (mixture of isomers) Atracurium Besylate (mixture of isomers)> Mixture of the cis-cis, cis-trans and trans-trans isomers of 2,2\\\'-[Pentane-1,5-diylbis[oxy(3-oxopropane-1,3-diyl)]]bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium] dibenzenesulfonate Atracurium besylateQ: What is Atracurium besylate Q: What is the CAS Number of Atracurium besylate Q: What is the storage condition of Atracurium besylate Q: What e the applications of Atracurium besylate AtracuriuM Besilete Atracurium BesyL Cisatracudum Besylate 51W89 |
| Description | Atracurium Besylate is a neuromuscular blocking agent with ED95 of 0.2 mg/kg. Target: nAChRAtracurium besylate is a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Atracurium is classified as an intermediate-duration non-depolarizing neuromuscular-blocking agent [1]. A 14C radiolabeled metabolism study in cats confirmed the lack of hepatic or renal involvement in the metabolism of atracurium: radioactivity eliminated in bile and urine was predominantly from metabolites rather than the unchanged parent drug [2]. |
|---|---|
| Related Catalog | |
| References |
| Melting Point | 85-90ºC |
|---|---|
| Molecular Formula | C65H82N2O18S2 |
| Molecular Weight | 1243.479 |
| Exact Mass | 1242.500366 |
| PSA | 257.60000 |
| LogP | 11.32610 |
| Storage condition | 2-8°C |
| Water Solubility | H2O: ~27 mg/mL |
| RIDADR | NONH for all modes of transport |
|---|---|
| WGK Germany | 3 |
|
~86%
64228-81-5 |
| Literature: Stenlake; Waigh; Dewar; et al. European Journal of Medicinal Chemistry, 1981 , vol. 16, # 6 p. 515 - 524 |
|
~%
64228-81-5 |
| Literature: European Journal of Medicinal Chemistry, , vol. 16, # 6 p. 515 - 524 |
|
~%
64228-81-5 |
| Literature: European Journal of Medicinal Chemistry, , vol. 16, # 6 p. 515 - 524 |
|
~%
64228-81-5 |
| Literature: European Journal of Medicinal Chemistry, , vol. 16, # 6 p. 515 - 524 |
|
~%
64228-81-5 |
| Literature: European Journal of Medicinal Chemistry, , vol. 16, # 6 p. 515 - 524 |
|
~%
64228-81-5 |
| Literature: European Journal of Medicinal Chemistry, , vol. 16, # 6 p. 515 - 524 |